Evidence map›Paper›PMID 37340068›Full record

ArticleScientific reports2023

Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue.

Judith Weber, Klara Djurberg, Sara Lundsten Salomonsson, Maria Kamprath, Aileen Hoehne, Hadis Westin, Fernanda Vergara, Sina Bondza

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Judith Weber3B Pharmaceuticals GmbH, Berlin, Germany.
Klara DjurbergRidgeview Instruments AB, Uppsala, Sweden.
Sara Lundsten SalomonssonRidgeview Instruments AB, Uppsala, Sweden.
Maria Kamprath3B Pharmaceuticals GmbH, Berlin, Germany.
Aileen Hoehne3B Pharmaceuticals GmbH, Berlin, Germany.
Hadis WestinRidgeview Instruments AB, Uppsala, Sweden.
Fernanda Vergara3B Pharmaceuticals GmbH, Berlin, Germany.
Sina BondzaRidgeview Instruments AB, Uppsala, Sweden. s.bondza@ridgeviewinstruments.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The quantification of the number of targets in biological systems is an important parameter to assess the suitability of surface markers as targets for drugs, drug delivery and medical imaging. Likewise, quantifying the interaction with the target in terms of affinity and binding kinetics is essential during drug development. Commonly used approaches to quantify membrane antigens on live cells are based on manual saturation techniques that are labour-intensive, require careful calibration of the generated signal and do not quantify the binding rates. Here, we present how measuring interactions in real-time on live cells and tissue under ligand depletion conditions can be used to simultaneously quantify the kinetic binding parameters as well as the number of available binding sites in a biological system. Suitable assay design was explored with simulated data and feasibility of the method verified with experimental data for exemplary low molecular weight peptide and antibody radiotracers as well as fluorescent antibodies. In addition to revealing the number of accessible target sites and improving the accuracy of binding kinetics and affinities, the presented method does not require knowledge about the absolute signal generated per ligand molecule. This enables a simplified workflow for use with both radioligands and fluorescent binders.

Indexed as

AntibodiesAntigensBinding SitesKineticsLigandsProtein BindingAntibodiesAntigensLigands

Identifiers

PMID37340068
PMCPMC10282064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.